Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
34/99

BSE: 532660 | NSE: VIVIMEDLAB

33.30
0.30 (0.91%)
18-Jan-2019 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  33.90
  •  33.90
  •  32.95
  •  33.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  220649
  •  73.48
  •  103.40
  •  32.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 273.15
  • 3.47
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 997.29
  • 1.21%
  • 0.32

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.58%
  • 4.18%
  • 34.35%
  • FII
  • DII
  • Others
  • 0.46%
  • 0.12%
  • 24.31%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.69
  • -2.57
  • -4.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.62
  • 3.09
  • -0.74

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.95
  • 3.26
  • -2.34

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.12
  • 6.74
  • 6.12

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.15
  • 1.04
  • 1.05

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.86
  • 5.77
  • 5.53

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
364.62
282.50
29.07%
358.54
317.97
12.76%
285.61
436.68
-34.60%
299.58
360.03
-16.79%
Expenses
314.42
219.90
42.98%
289.74
251.51
15.20%
251.87
259.53
-2.95%
250.68
260.03
-3.60%
EBITDA
50.20
62.60
-19.81%
68.80
66.47
3.51%
33.74
177.15
-80.95%
48.89
100.01
-51.11%
EBIDTM
13.77%
22.16%
19.19%
20.90%
11.82%
40.57%
16.32%
27.78%
Other Income
5.04
0.61
726.23%
5.75
2.66
116.17%
2.87
2.32
23.71%
3.12
3.08
1.30%
Interest
17.59
21.36
-17.65%
19.28
24.23
-20.43%
16.37
18.38
-10.94%
17.18
17.34
-0.92%
Depreciation
19.58
16.09
21.69%
15.87
12.56
26.35%
13.84
12.60
9.84%
13.94
15.47
-9.89%
PBT
18.07
25.78
-29.91%
39.40
32.34
21.83%
6.41
148.49
-95.68%
20.89
70.28
-70.28%
Tax
-0.21
3.71
-
10.95
8.44
29.74%
-2.50
41.51
-
-0.03
18.57
-
PAT
18.28
22.07
-17.17%
28.46
23.91
19.03%
8.91
106.98
-91.67%
20.92
51.71
-59.54%
PATM
5.01%
7.81%
7.94%
7.52%
3.12%
24.50%
6.98%
14.36%
EPS
2.21
2.69
-17.84%
3.45
2.92
18.15%
1.30
13.20
-90.15%
2.53
6.38
-60.34%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
1,308.35
1,185.66
1,461.91
1,345.63
1,380.10
1,350.83
1,108.80
668.31
416.00
343.49
276.12
Net Sales Growth
-6.36%
-18.90%
8.64%
-2.50%
2.17%
21.83%
65.91%
60.65%
21.11%
24.40%
 
Cost Of Goods Sold
529.10
479.67
536.28
624.05
646.23
656.33
513.27
337.39
236.97
203.49
160.67
Gross Profit
779.25
705.99
925.63
721.58
733.88
694.51
595.52
330.93
179.03
140.00
115.46
GP Margin
59.56%
59.54%
63.32%
53.62%
53.18%
51.41%
53.71%
49.52%
43.04%
40.76%
41.82%
Total Expenditure
1,106.71
970.79
1,057.46
1,122.68
1,158.21
1,166.29
928.00
538.02
329.44
279.13
229.96
Power & Fuel Cost
-
34.73
34.78
38.26
46.70
51.39
44.06
22.33
11.08
8.28
6.62
% Of Sales
-
2.93%
2.38%
2.84%
3.38%
3.80%
3.97%
3.34%
2.66%
2.41%
2.40%
Employee Cost
-
197.78
189.98
176.94
184.43
162.66
50.33
32.19
19.97
22.07
16.77
% Of Sales
-
16.68%
13.00%
13.15%
13.36%
12.04%
4.54%
4.82%
4.80%
6.43%
6.07%
Manufacturing Exp.
-
176.69
175.06
167.31
179.26
182.37
230.50
91.61
32.06
19.82
22.86
% Of Sales
-
14.90%
11.97%
12.43%
12.99%
13.50%
20.79%
13.71%
7.71%
5.77%
8.28%
General & Admin Exp.
-
78.75
93.93
95.26
76.30
86.64
69.34
31.42
15.96
15.29
12.80
% Of Sales
-
6.64%
6.43%
7.08%
5.53%
6.41%
6.25%
4.70%
3.84%
4.45%
4.64%
Selling & Distn. Exp.
-
16.66
15.39
20.86
25.29
26.91
20.50
23.09
11.26
9.32
7.82
% Of Sales
-
1.41%
1.05%
1.55%
1.83%
1.99%
1.85%
3.45%
2.71%
2.71%
2.83%
Miscellaneous Exp.
-
-13.49
12.03
0.00
0.00
0.00
0.00
0.00
2.14
0.86
7.82
% Of Sales
-
-1.14%
0.82%
0%
0%
0%
0%
0%
0.51%
0.25%
0.88%
EBITDA
201.63
214.87
404.45
222.95
221.89
184.54
180.80
130.29
86.56
64.36
46.16
EBITDA Margin
15.41%
18.12%
27.67%
16.57%
16.08%
13.66%
16.31%
19.50%
20.81%
18.74%
16.72%
Other Income
16.78
9.61
8.09
23.63
8.02
35.90
26.33
2.68
1.00
6.84
2.53
Interest
70.42
82.35
67.79
85.26
86.20
67.46
50.44
28.37
22.10
22.82
18.43
Depreciation
63.23
56.42
58.28
61.39
66.18
66.12
58.81
26.79
10.20
8.73
7.15
PBT
84.77
85.71
286.48
99.93
77.54
86.86
97.88
77.82
55.26
39.65
23.11
Tax
8.21
9.62
72.50
16.26
5.49
20.47
14.29
14.68
6.43
8.63
3.76
Tax Rate
9.69%
11.22%
25.31%
16.27%
7.08%
23.57%
14.60%
18.86%
11.64%
21.77%
16.27%
PAT
76.57
77.94
213.97
83.67
72.05
66.39
83.58
63.14
48.83
31.01
19.35
PAT before Minority Interest
78.42
76.09
213.97
83.67
72.05
66.39
83.58
63.14
48.83
31.01
19.35
Minority Interest
1.85
1.85
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
5.85%
6.57%
14.64%
6.22%
5.22%
4.91%
7.54%
9.45%
11.74%
9.03%
7.01%
PAT Growth
-62.59%
-63.57%
155.73%
16.13%
8.53%
-20.57%
32.37%
29.31%
57.47%
60.26%
 
Unadjusted EPS
9.49
9.22
26.41
51.64
44.47
40.97
52.04
45.31
48.04
31.12
20.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
1,226.40
734.21
585.15
559.24
560.36
509.14
474.79
196.71
144.86
102.55
Share Capital
341.73
16.20
80.15
80.15
80.15
80.01
144.88
10.16
9.96
9.40
Total Reserves
884.67
718.01
505.00
479.09
477.84
426.77
327.54
177.68
129.94
90.81
Non-Current Liabilities
356.86
503.86
561.11
538.36
532.58
449.68
360.72
148.25
251.48
313.50
Secured Loans
275.90
396.25
206.75
436.44
378.81
255.19
258.03
131.90
234.55
223.77
Unsecured Loans
49.30
57.07
50.52
46.94
40.92
41.73
53.35
0.00
0.74
76.70
Long Term Provisions
7.03
2.19
3.57
3.17
5.16
1.47
1.06
1.69
0.00
0.00
Current Liabilities
790.23
817.39
897.41
800.86
744.42
610.73
463.69
242.44
59.38
31.35
Trade Payables
201.99
178.59
166.74
188.71
190.49
166.28
156.86
44.06
42.35
20.74
Other Current Liabilities
147.64
179.92
285.85
176.38
138.78
116.10
40.79
4.68
0.04
0.01
Short Term Borrowings
385.16
381.47
407.76
389.38
375.43
301.13
232.82
175.08
0.00
0.00
Short Term Provisions
55.43
77.41
37.06
46.39
39.71
27.22
33.21
18.61
17.00
10.61
Total Liabilities
2,385.77
2,055.46
2,043.67
1,898.46
1,837.36
1,569.55
1,299.20
587.40
455.72
447.40
Net Block
1,035.36
878.90
814.17
813.47
807.92
709.04
595.35
264.29
254.72
228.50
Gross Block
1,128.64
915.77
1,663.33
1,599.11
1,526.04
1,329.52
1,167.48
812.71
289.11
254.16
Accumulated Depreciation
93.29
36.87
849.16
785.64
718.12
620.49
572.13
548.42
34.39
25.66
Non Current Assets
1,103.83
961.04
911.03
906.45
846.28
736.20
604.41
266.01
255.86
255.38
Capital Work in Progress
65.27
76.13
94.17
90.28
38.12
26.92
8.37
1.73
1.14
26.88
Non Current Investment
2.70
2.71
2.69
2.70
0.24
0.24
0.70
0.00
0.00
0.00
Long Term Loans & Adv.
0.00
2.81
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.50
0.50
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,281.94
1,094.42
1,132.60
991.96
970.90
815.08
647.14
314.68
194.06
183.27
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
540.17
483.97
490.80
431.43
426.66
340.26
247.88
84.47
79.35
69.13
Sundry Debtors
275.43
200.14
326.24
329.58
347.83
308.23
221.61
127.56
93.86
70.75
Cash & Bank
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
16.98
Other Current Assets
367.32
22.53
11.73
19.07
161.84
142.64
141.32
91.55
15.23
26.41
Short Term Loans & Adv.
337.73
332.31
272.88
185.21
139.50
119.82
141.09
89.45
15.20
26.40
Net Current Assets
491.71
277.03
235.19
191.10
226.47
204.35
183.45
72.25
134.67
151.91
Total Assets
2,385.77
2,055.46
2,043.67
1,898.45
1,837.36
1,569.55
1,299.21
587.39
455.73
447.41

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
21.42
57.96
154.12
140.48
-117.65
90.11
45.17
23.89
55.13
-16.82
PBT
85.71
286.48
99.93
77.54
86.86
97.88
77.81
55.26
39.65
23.11
Adjustment
135.90
124.15
101.94
111.32
101.31
80.43
55.16
32.30
30.82
24.98
Changes in Working Capital
-158.14
-315.94
-47.75
-48.38
-305.83
-94.13
-87.81
-63.67
5.89
-47.65
Cash after chg. in Working capital
63.48
94.69
154.12
140.48
-117.65
84.18
45.17
23.89
76.36
0.45
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-42.06
-36.73
0.00
0.00
0.00
5.93
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-163.53
-68.49
-190.42
-106.71
-291.11
-169.59
-424.15
-72.39
-7.13
-161.07
Net Fixed Assets
38.52
-25.51
-6.97
-49.04
-16.56
-128.68
-148.52
-26.78
7.77
-58.31
Net Investments
-64.27
142.45
0.00
-2.50
-132.00
-8.38
-83.77
0.09
-0.98
0.00
Others
-137.78
-185.43
-183.45
-55.17
-142.55
-32.53
-191.86
-45.70
-13.92
-102.76
Cash from Financing Activity
185.66
35.05
40.59
-41.67
419.37
67.10
404.22
53.98
-59.36
179.33
Net Cash Inflow / Outflow
43.56
24.51
4.29
-7.90
10.62
-12.38
25.24
5.47
-11.35
1.43
Opening Cash & Equivalents
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
16.98
15.54
Closing Cash & Equivalent
99.03
55.47
30.96
26.67
34.57
23.96
36.34
11.10
5.62
16.98

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
104.60
85.93
64.20
61.00
58.36
52.74
42.03
35.45
26.71
19.24
ROA
3.43%
10.44%
4.25%
3.86%
3.90%
5.83%
6.69%
9.36%
6.87%
5.56%
ROE
9.76%
35.18%
16.50%
14.90%
14.81%
23.34%
26.70%
31.18%
27.74%
23.35%
ROCE
9.04%
21.86%
11.93%
10.91%
11.93%
13.83%
14.29%
17.80%
16.30%
14.14%
Fixed Asset Turnover
1.16
1.13
0.82
0.88
0.95
0.89
0.67
0.76
1.26
1.53
Receivable days
73.20
65.71
88.94
89.58
88.63
87.21
95.35
97.13
87.46
84.05
Inventory Days
157.64
121.69
125.08
113.47
103.61
96.80
90.76
71.87
78.89
76.23
Payable days
70.90
60.76
60.42
57.00
57.11
62.91
65.22
47.96
41.69
34.59
Cash Conversion Cycle
159.93
126.64
153.61
146.05
135.14
121.10
120.89
121.04
124.66
125.69
Total Debt/Equity
0.69
1.45
1.63
1.81
1.66
1.36
1.33
1.70
1.77
3.32
Interest Cover
2.04
5.23
2.17
1.90
2.29
2.94
3.74
3.50
2.74
2.25

News Update:


  • Vivimed Labs’ JV gets USFDA’s approval for Albendazole Tablets
    12th Dec 2018, 12:06 PM

    The US market for Albendazole Tablets USP 200 mg is approximately $100 million

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.